Drug reference

Cemiplimab

Monoclonal Antibody · Antineoplastic

Monoclonal AntibodyAntineoplastic

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

Manufacturer advises females of childbearing potential should use effective contraception during treatment and for at least 4 months after the last dose.

FDA category + note

Mechanism

Cemiplimab is a human immunoglobulin G4 monoclonal antibody. It functions by binding to the programmed death-1 (PD-1) receptor. This binding potentiates an immune response against tumour cells.

Indications

Cutaneous squamous cell carcinoma (specialist use only)cancer therapyadvanced cutaneous squamousbasal cell carcinomafirst-line treatment of patients with locally advanced or metastatic NSCLC with high PD-L1BCC patients who progress after targeted therapyadvanced squamous cell carcinomaneoadjuvant therapy in stage II, III and IV squamous cell carcinoma

Dosing

Adult: 350 mg every 3 weeks, for dose interruption or discontinuation of treatment due to side-effects or infusion-related reactions consult product literature

Side effects

Common

Arthralgiaarthritisastheniacolitisdiarrhoeahepatic disordershyperthyroidismhypothyroidisminfusion related reactionmyalgiapainpneumonitisskin reactionsstomatitis

Serious

Adrenal insufficiency
cardiac inflammation
diabetic ketoacidosis
encephalitis
hypophysitis
immune thrombocytopenic purpura
keratitis
meningitis
muscle weakness
myasthenia gravis
nephritis
nerve disorders
nervous system disorders
Sjögren syndrome
thyroiditis
type 1 diabetes mellitus
vasculitis
Encephalitis non-infective
severe cutaneous adverse reactions (SCARs)
immune-related inflammation

Pregnancy & lactation

Pregnancy

Manufacturer advises females of childbearing potential should use effective contraception during treatment and for at least 4 months after the last dose.